The OMERACT giant cell arteritis ultrasonography score: a potential predictive outcome for assessing the risk of relapse during follow-up
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Lack of improvement in the OMERACT GCA US Score (OGUS) during treatment indicates a higher probability of relapse in Giant Cell Arteritis (GCA) patients and predicts absence of remission.
Area Of Science
- Rheumatology
- Internal Medicine
- Diagnostic Imaging
Background
- Giant Cell Arteritis (GCA) is a systemic vasculitis affecting large arteries, primarily the aorta and its branches.
- Early diagnosis and effective management are crucial to prevent severe complications such as vision loss and stroke.
- Ultrasound (US) is increasingly used to assess disease activity and guide treatment in GCA.
Purpose Of The Study
- To evaluate if changes in the OMERACT GCA US Score (OGUS) after treatment can predict relapse in GCA patients.
- To determine the utility of OGUS changes in assessing the likelihood of remission at 6 months post-treatment.
Main Methods
- A multicentre retrospective study involving 76 GCA patients from fast-track clinics over two years.
- Patients underwent serial US evaluations at baseline, 3 months, and 6 months.
- OGUS changes were analyzed in relation to European Alliance of Associations for Rheumatology (EULAR) criteria for remission and relapse at 6 months.
Main Results
- Nineteen percent of patients experienced relapse by 6 months; 43.8% achieved remission.
- Non-relapsing patients showed significant OGUS improvement between baseline and 6 months (P=0.004).
- Patients who relapsed or did not achieve remission exhibited no significant OGUS improvement during follow-up.
Conclusions
- Absence of OGUS improvement during follow-up in GCA patients is a potential indicator of relapse.
- Lack of OGUS change may predict the absence of remission at 6 months.
- OGUS monitoring could aid in identifying GCA patients at risk for disease recurrence.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
